Welcome to our dedicated page for NYMX news (Ticker: NYMX), a resource for investors and traders seeking the latest updates and insights on NYMX stock.
Nymox Pharmaceutical Corporation (NYSE: NYMX) delivers innovative solutions for age-related health conditions through its biopharmaceutical research and diagnostic technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and regulatory milestones.
Access timely information about Fexapotide Triflutate (NX-1207) clinical trials for prostate conditions, patent developments for NYMOZARFEX therapies, and updates on diagnostic tools like Alzheimalert. Our curated news collection features press releases covering trial results, intellectual property achievements, and strategic corporate developments.
Key updates include progress reports on Phase II studies for low-grade prostate cancer treatments, regulatory filings for Alzheimer's diagnostic tools, and analyses of market expansion strategies. Bookmark this page to monitor how Nymox's pipeline advancements could impact long-term therapeutic landscapes.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced the submission of its New Drug Application (NDA) to the FDA for Fexapotide Triflutate, aimed at treating benign prostatic hyperplasia (BPH). This marks a significant step towards potential marketing approval in the U.S. However, the company highlighted that there are no guarantees regarding the submission outcomes. Nymox plans to submit applications in other major markets shortly and will continue to update stakeholders on the application process and related developments.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has completed essential preparations for its upcoming regulatory submission for Fexapotide Triflutate, aimed at treating Benign Prostatic Hyperplasia (BPH). CEO Paul Averback expressed satisfaction with overcoming recent delays and noted that the submission application timeline will be communicated promptly. Clinical trials revealed Fexapotide's significant benefits, including low prostate cancer incidence and acute urinary retention rates, suggesting a promising treatment alternative for patients intolerant of standard medications.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced its participation in the Torrey Hills Capital Emerging Growth Conference in San Diego this week. The company expressed enthusiasm for networking with high-caliber investors and plans to make additional presentations to the investment community. Nymox specializes in developing therapeutics targeting unmet needs of the aging male population, particularly its lead drug candidate, Fexapotide Triflutate (FT), which has completed Phase 3 trials involving over 1,700 patients and is preparing for approval applications in the U.S. and Europe.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced a positive update on the progress of its Fexapotide filing, confirming that key vendor documentation has been completed. CEO Paul Averback highlighted that standard quality control steps are underway, with a future update anticipated soon. The company also plans to participate in investor conferences in the upcoming months. Fexapotide Triflutate, the lead candidate for benign prostatic hyperplasia, has completed Phase 3 trials across over 70 clinical centers and is preparing for global regulatory submissions.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced progress on its BPH treatment product, Fexapotide Triflutate. The company has completed all tasks for the upcoming filing process, with only minor delays due to third-party documentation. Nymox has received regulatory acceptance for proposed brand names and is set to file for patents in several jurisdictions, enhancing its intellectual property protection. CEO Dr. Paul Averback expressed confidence in the company’s progress, indicating that the filing will happen soon with updates promised within 30 days.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is set to file for marketing approval of Fexapotide Triflutate for benign prostatic hyperplasia (BPH) by September 15, 2021. CEO Dr. Paul Averback expressed hopes for an earlier filing. The clinical development of Fexapotide involved over 1,700 patients across more than 70 centers in the U.S. This move is crucial for addressing unmet needs in the aging male population. However, the company acknowledges the inherent risks and uncertainties in the drug approval process.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced a private placement of 3,669,724 shares of common stock and warrants for 1,834,862 shares at a price of $2.18, totaling approximately $8 million before expenses. The warrants have an exercise price of $2.50 and are valid for five years. Proceeds will be used for working capital and corporate purposes. The transaction is expected to close by April 30, 2021, subject to customary conditions. Nymox is focused on developing treatments for benign prostatic hyperplasia with its lead candidate, Fexapotide Triflutate.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced its plans to file for regulatory approval of Fexapotide Triflutate, a novel treatment for BPH, by summer 2021. The exact filing date will be shared within six weeks. CEO Paul Averback expressed confidence in their timeline and the product's potential to improve men's health significantly. He highlighted that current BPH treatments have not changed in over 30 years, marking this as a crucial development. The company is committed to transparency and will update on any delays.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced significant progress in the regulatory filing of Fexapotide Triflutate (FT) for benign prostatic hyperplasia (BPH). Delays were primarily due to extensive data requirements and Covid-related inefficiencies. The company is confident that filings will be completed in Q1 2021. Management invested USD $510,000 in the company's shares recently. Additionally, nine new international patents for FT have been issued, enhancing product coverage. FT shows promise for treating BPH and early prostate cancer with long-term efficacy and fewer side effects.
